1. What It Is (Mechanism of Action)
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist at the ghrelin/growth hormone secretagogue receptor (GHSR-1a). Unlike older GHRPs (GHRP-2, GHRP-6), it stimulates pituitary GH release with minimal stimulation of ACTH, cortisol, or prolactin.
2. Clinical Indications Under Study
Investigated clinically for postoperative bowel recovery (postoperative ileus) following bowel resection.
3. FDA Approval & Regulatory Status
Unapproved for Human Use (FDA 503A Category 2 List)
4. Human Clinical Evidence Summary
5. Known Risks, Side Effects & Boxed Warnings
Transient flushing, headaches, decreased insulin sensitivity, lightheadedness, and elevated IGF-1 risk factors. WADA prohibited substance under Category S2.
6. Legal, Prescription & Compounding Status
Listed under FDA Category 2 Bulk Drug Substances, restricting pharmacy compounding in the United States.
7. Why Gray-Market "Research Chemical" Versions Are Risky
Get Breaking Ipamorelin Clinical Trial Alerts
Receive verified FDA dockets, Phase 3 readouts, and independent HPLC lab audits directly from our medical journalism desk.
Clinical trials · FDA decisions · Laboratory testing
8. Questions to Ask a Licensed Clinician
If you are discussing this compound with your doctor or healthcare provider, consider bringing these evidence-based questions:
- Q1: How does selective GHSR-1a agonism differ from physiological pulsatile GH release?
- Q2: What are the established clinical alternatives for patients with confirmed adult growth hormone deficiency?
9. Primary Peer-Reviewed Sources & Citations
- [1] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed / Source →
- [2] FDA 503A Bulks Advisory Review: Growth Hormone Secretagogue Peptides. PubMed / Source →